polatuzumab vedotin
roche
['polatuzumab', 'lymphoma', 'dlbcl']
polatuzumab-r-ice as 2l in dlbcl, by dr alex f herrera n=41
eot orr 80%, cr 56%
61% bridged to asct
poor outcome in primary refractory prior to polar-ice
short follow-up #lymphoma #ash22 
Medical degree at @USAL | Internal Medicine student at @HematoCAUSA | Hematology and Hemotherapy at Hospital Ramón y Cajal @HematoRYC | PhD student at @UAHes